Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02282644

Acronym

PROMET II

Enrollment

Registered

2014-11-04

Start date

2014-09-08

Completion date

2017-08-25

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Brief summary

The recent data suggest that cancer cells at the origin of prostate cancer metastases can be detected in an early stage. Available techniques allow phenotypic analysis of cancer cells in circulating blood (cellsearch) or in marrow hematopoietic (flow cytometry). Pilot study on 180 patients infected by prostate cancer at all stage of disease, show that c-met marker , integrin alpha 2 and 6 expressed in marrow and quantified by flow cytometry were predictor of metastatic progress. In this new study the investigators will analyze antibody panel by cellsearch and flow cytometry on marrow sample of castration-Resistant prostate cancer patients.

Interventions

BIOLOGICALBone marrow sampling

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Histologically confirmed adenocarcinoma or prostate * Ongoing effective androgen deprivation therapy (testosterone ≤ 50 ng/mL) * Castration-Resistant prostate cancer patient : defined as a minimum of 3 rising PSA values assessed and/or radiological progress confirmed by RECIST and PCWG2 * Patient who signed informed consent

Exclusion criteria

* Severe disorders of coagulation * Major skin lesion on iliac crests * Allergies in local anesthetics * Psychological instability or psychiatric histories * Uncertain follow-up and distant residence * History of another invasive cancer and hematologic disease * Patient deprived of their freedom by court or administrative order * Revocation of consent

Design outcomes

Primary

Measure	Time frame
Risk of death according to positive makers	Two years

Secondary

Measure	Time frame
Risk of clinical progression according to positive markers.	Two years
Risk of biological progression according to positive markers.	Two years
Risk of radiological progression according to positive markers.	Two years

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026